Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances
Treatment-emergent weight gain has been reported in younger patients receiving atypical antipsychotics, but less is known about weight gain in adults aged 65 years and older. This was a post hoc analysis of 1267 patients with dementia and behavioral disturbances treated with olanzapine (1 to 20 mg/d...
Gespeichert in:
| Veröffentlicht in: | Journal of geriatric psychiatry and neurology 2007-06, Vol.20 (2), p.107-114 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114 |
|---|---|
| container_issue | 2 |
| container_start_page | 107 |
| container_title | Journal of geriatric psychiatry and neurology |
| container_volume | 20 |
| creator | Lipkovich, Ilya Ahl, Jonna Nichols, Russell Hardy, Thomas Poole Hoffmann, Vicki |
| description | Treatment-emergent weight gain has been reported in younger patients receiving atypical antipsychotics, but less is known about weight gain in adults aged 65 years and older. This was a post hoc analysis of 1267 patients with dementia and behavioral disturbances treated with olanzapine (1 to 20 mg/d) in clinical trials, most of whom were underweight (body mass index |
| doi_str_mv | 10.1177/0891988706298629 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_21201006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A164807346</galeid><sage_id>10.1177_0891988706298629</sage_id><sourcerecordid>A164807346</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-2641e7a218907c0ba80d07cc4a7079df3933cc85d8a793eab5e69554a03c3b5c3</originalsourceid><addsrcrecordid>eNp1kd-L1DAQx4Mo3nr67pMEQd96Jk3TpI97u_6Cg_Ph5B7LNJ12c7TpbpIK-teb0oUTUUJIJvP5ZpL5EvKasyvOlfrAdMUrrRUr80qn-YRsuJR5JhXTT8lmSWdL_oK8COGBMSYrLZ6TC65koZXmG3K6R9sfIt0dwPUY6H721vX0ziPEEV2k9zYe6O0A7hccrUNqXYpa9HTbzkOk3yDahIWV2-OisUDBtfQaD_DDTh4Gurchzr4BZzC8JM86GAK-Oq-X5Punj3e7L9nN7eevu-1NZooyj1leFhwV5FxXTBnWgGZt2pgCFFNV24lKCGO0bDWoSiA0EstKygKYMKKRRlyS9-u9Rz-dZgyxHm0wOKSv4DSHOuc544yVCXy7gj0MWFvXTdGDMUd7qnlZaKZEsUBX_4DSaHG0ZnLY2XS-_VPAVoHxUwgeu_ro7Qj-Z81ZvZhX_21ekrw5v3huRmwfBWe3EvDuDEAwMHQ-NdSGRy5BSkiWuGzlAvRYP0yzd6nT_y_8G1barTU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21201006</pqid></control><display><type>article</type><title>Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Lipkovich, Ilya ; Ahl, Jonna ; Nichols, Russell ; Hardy, Thomas ; Poole Hoffmann, Vicki</creator><creatorcontrib>Lipkovich, Ilya ; Ahl, Jonna ; Nichols, Russell ; Hardy, Thomas ; Poole Hoffmann, Vicki</creatorcontrib><description>Treatment-emergent weight gain has been reported in younger patients receiving atypical antipsychotics, but less is known about weight gain in adults aged 65 years and older. This was a post hoc analysis of 1267 patients with dementia and behavioral disturbances treated with olanzapine (1 to 20 mg/d) in clinical trials, most of whom were underweight (body mass index <18.5 kg/m2) or of normal weight (body mass index, 18.5-24.9 kg/m2) at baseline. Weight changes over the first 20 weeks of treatment in olanzapine-treated patients, as estimated by a repeated measures analysis model, were significantly greater in the combined categories of underweight and normal weight (1.22 kg and 1.29 kg, respectively) versus overweight and obese (0.56 kg and 0.53 kg, respectively; P = .006). The estimated probability of gaining more than 7% of initial body weight was significantly greater in patients treated with olanzapine versus active comparator (P < .001) or placebo (P < .001). Weight gain in olanzapine-treated older patients with dementia and behavioral disturbances was significantly greater in individuals with a baseline body mass index of less than 25 kg/m2. (J Geriatr Psychiatry Neurol 2007;20:107-114)</description><identifier>ISSN: 0891-9887</identifier><identifier>EISSN: 1552-5708</identifier><identifier>DOI: 10.1177/0891988706298629</identifier><identifier>PMID: 17548781</identifier><language>eng</language><publisher>Los Angeles, CA: Sage Publications</publisher><subject>Age Factors ; Aged ; Aged, 80 and over ; Alzheimer Disease - diagnosis ; Alzheimer Disease - drug therapy ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Benzodiazepines - adverse effects ; Benzodiazepines - therapeutic use ; Biological and medical sciences ; Body Mass Index ; Body weight ; Body Weight - drug effects ; Clinical Trials as Topic ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dementia ; Dosage and administration ; Dose-Response Relationship, Drug ; Drug therapy ; Fundamental and applied biological sciences. Psychology ; Geriatrics ; Humans ; Medical sciences ; Mental Disorders - diagnosis ; Mental Disorders - drug therapy ; Neurology ; Olanzapine ; Physiological aspects ; Product Surveillance, Postmarketing ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Vertebrates: nervous system and sense organs</subject><ispartof>Journal of geriatric psychiatry and neurology, 2007-06, Vol.20 (2), p.107-114</ispartof><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2007 Sage Publications, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-2641e7a218907c0ba80d07cc4a7079df3933cc85d8a793eab5e69554a03c3b5c3</citedby><cites>FETCH-LOGICAL-c462t-2641e7a218907c0ba80d07cc4a7079df3933cc85d8a793eab5e69554a03c3b5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0891988706298629$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0891988706298629$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18787350$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17548781$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lipkovich, Ilya</creatorcontrib><creatorcontrib>Ahl, Jonna</creatorcontrib><creatorcontrib>Nichols, Russell</creatorcontrib><creatorcontrib>Hardy, Thomas</creatorcontrib><creatorcontrib>Poole Hoffmann, Vicki</creatorcontrib><title>Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances</title><title>Journal of geriatric psychiatry and neurology</title><addtitle>J Geriatr Psychiatry Neurol</addtitle><description>Treatment-emergent weight gain has been reported in younger patients receiving atypical antipsychotics, but less is known about weight gain in adults aged 65 years and older. This was a post hoc analysis of 1267 patients with dementia and behavioral disturbances treated with olanzapine (1 to 20 mg/d) in clinical trials, most of whom were underweight (body mass index <18.5 kg/m2) or of normal weight (body mass index, 18.5-24.9 kg/m2) at baseline. Weight changes over the first 20 weeks of treatment in olanzapine-treated patients, as estimated by a repeated measures analysis model, were significantly greater in the combined categories of underweight and normal weight (1.22 kg and 1.29 kg, respectively) versus overweight and obese (0.56 kg and 0.53 kg, respectively; P = .006). The estimated probability of gaining more than 7% of initial body weight was significantly greater in patients treated with olanzapine versus active comparator (P < .001) or placebo (P < .001). Weight gain in olanzapine-treated older patients with dementia and behavioral disturbances was significantly greater in individuals with a baseline body mass index of less than 25 kg/m2. (J Geriatr Psychiatry Neurol 2007;20:107-114)</description><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Benzodiazepines - adverse effects</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Body Mass Index</subject><subject>Body weight</subject><subject>Body Weight - drug effects</subject><subject>Clinical Trials as Topic</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dementia</subject><subject>Dosage and administration</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Mental Disorders - diagnosis</subject><subject>Mental Disorders - drug therapy</subject><subject>Neurology</subject><subject>Olanzapine</subject><subject>Physiological aspects</subject><subject>Product Surveillance, Postmarketing</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0891-9887</issn><issn>1552-5708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kd-L1DAQx4Mo3nr67pMEQd96Jk3TpI97u_6Cg_Ph5B7LNJ12c7TpbpIK-teb0oUTUUJIJvP5ZpL5EvKasyvOlfrAdMUrrRUr80qn-YRsuJR5JhXTT8lmSWdL_oK8COGBMSYrLZ6TC65koZXmG3K6R9sfIt0dwPUY6H721vX0ziPEEV2k9zYe6O0A7hccrUNqXYpa9HTbzkOk3yDahIWV2-OisUDBtfQaD_DDTh4Gurchzr4BZzC8JM86GAK-Oq-X5Punj3e7L9nN7eevu-1NZooyj1leFhwV5FxXTBnWgGZt2pgCFFNV24lKCGO0bDWoSiA0EstKygKYMKKRRlyS9-u9Rz-dZgyxHm0wOKSv4DSHOuc544yVCXy7gj0MWFvXTdGDMUd7qnlZaKZEsUBX_4DSaHG0ZnLY2XS-_VPAVoHxUwgeu_ro7Qj-Z81ZvZhX_21ekrw5v3huRmwfBWe3EvDuDEAwMHQ-NdSGRy5BSkiWuGzlAvRYP0yzd6nT_y_8G1barTU</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Lipkovich, Ilya</creator><creator>Ahl, Jonna</creator><creator>Nichols, Russell</creator><creator>Hardy, Thomas</creator><creator>Poole Hoffmann, Vicki</creator><general>Sage Publications</general><general>Decker</general><general>Sage Publications, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20070601</creationdate><title>Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances</title><author>Lipkovich, Ilya ; Ahl, Jonna ; Nichols, Russell ; Hardy, Thomas ; Poole Hoffmann, Vicki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-2641e7a218907c0ba80d07cc4a7079df3933cc85d8a793eab5e69554a03c3b5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Benzodiazepines - adverse effects</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Body Mass Index</topic><topic>Body weight</topic><topic>Body Weight - drug effects</topic><topic>Clinical Trials as Topic</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dementia</topic><topic>Dosage and administration</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Mental Disorders - diagnosis</topic><topic>Mental Disorders - drug therapy</topic><topic>Neurology</topic><topic>Olanzapine</topic><topic>Physiological aspects</topic><topic>Product Surveillance, Postmarketing</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lipkovich, Ilya</creatorcontrib><creatorcontrib>Ahl, Jonna</creatorcontrib><creatorcontrib>Nichols, Russell</creatorcontrib><creatorcontrib>Hardy, Thomas</creatorcontrib><creatorcontrib>Poole Hoffmann, Vicki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of geriatric psychiatry and neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lipkovich, Ilya</au><au>Ahl, Jonna</au><au>Nichols, Russell</au><au>Hardy, Thomas</au><au>Poole Hoffmann, Vicki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances</atitle><jtitle>Journal of geriatric psychiatry and neurology</jtitle><addtitle>J Geriatr Psychiatry Neurol</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>20</volume><issue>2</issue><spage>107</spage><epage>114</epage><pages>107-114</pages><issn>0891-9887</issn><eissn>1552-5708</eissn><abstract>Treatment-emergent weight gain has been reported in younger patients receiving atypical antipsychotics, but less is known about weight gain in adults aged 65 years and older. This was a post hoc analysis of 1267 patients with dementia and behavioral disturbances treated with olanzapine (1 to 20 mg/d) in clinical trials, most of whom were underweight (body mass index <18.5 kg/m2) or of normal weight (body mass index, 18.5-24.9 kg/m2) at baseline. Weight changes over the first 20 weeks of treatment in olanzapine-treated patients, as estimated by a repeated measures analysis model, were significantly greater in the combined categories of underweight and normal weight (1.22 kg and 1.29 kg, respectively) versus overweight and obese (0.56 kg and 0.53 kg, respectively; P = .006). The estimated probability of gaining more than 7% of initial body weight was significantly greater in patients treated with olanzapine versus active comparator (P < .001) or placebo (P < .001). Weight gain in olanzapine-treated older patients with dementia and behavioral disturbances was significantly greater in individuals with a baseline body mass index of less than 25 kg/m2. (J Geriatr Psychiatry Neurol 2007;20:107-114)</abstract><cop>Los Angeles, CA</cop><pub>Sage Publications</pub><pmid>17548781</pmid><doi>10.1177/0891988706298629</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-9887 |
| ispartof | Journal of geriatric psychiatry and neurology, 2007-06, Vol.20 (2), p.107-114 |
| issn | 0891-9887 1552-5708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21201006 |
| source | MEDLINE; SAGE Complete |
| subjects | Age Factors Aged Aged, 80 and over Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Benzodiazepines - adverse effects Benzodiazepines - therapeutic use Biological and medical sciences Body Mass Index Body weight Body Weight - drug effects Clinical Trials as Topic Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dementia Dosage and administration Dose-Response Relationship, Drug Drug therapy Fundamental and applied biological sciences. Psychology Geriatrics Humans Medical sciences Mental Disorders - diagnosis Mental Disorders - drug therapy Neurology Olanzapine Physiological aspects Product Surveillance, Postmarketing Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Vertebrates: nervous system and sense organs |
| title | Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T03%3A37%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Weight%20Changes%20During%20Treatment%20With%20Olanzapine%20in%20Older%20Adult%20Patients%20With%20Dementia%20and%20Behavioral%20Disturbances&rft.jtitle=Journal%20of%20geriatric%20psychiatry%20and%20neurology&rft.au=Lipkovich,%20Ilya&rft.date=2007-06-01&rft.volume=20&rft.issue=2&rft.spage=107&rft.epage=114&rft.pages=107-114&rft.issn=0891-9887&rft.eissn=1552-5708&rft_id=info:doi/10.1177/0891988706298629&rft_dat=%3Cgale_proqu%3EA164807346%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21201006&rft_id=info:pmid/17548781&rft_galeid=A164807346&rft_sage_id=10.1177_0891988706298629&rfr_iscdi=true |